A role for the cell cycle phosphatase Cdc25a in vitamin D-dependent inhibition of adult rat vascular smooth muscle cell proliferation.
We have explored the mechanism(s) underlying 1,25 dihydroxyvitamin D's (1,25(OH)(2)D) suppression of agonist-induced vascular smooth muscle cell (VSMC) proliferation. Quiescent cultured adult rat VSMC were treated with 1,25(OH)(2)D for 48h and endothelin (ET) or angiotensin II (AII) for the final 24h. We show that VSMC responded to 1,25(OH)(2)D or its less hypercalcemic analogue RO 25-6760 with ∼70% inhibition of ET-dependent (3)H-thymidine incorporation. The inhibition was linked to a comparable reduction in ET-stimulated cyclin-dependent kinase 2 (Cdk2) activity and suppression of an ET-induced Cdk2 activator, cell division cycle 25 homolog A (Cdc25A). Both 1,25(OH)(2)D and RO 25-6760 completely inhibited the ET-dependent increase in Cdc25A mRNA and protein levels, phosphatase and promoter activities. 1,25(OH)(2)D also suppressed AII-induced DNA synthesis, Cdk2 activity and Cdc25A gene transcription. Inhibition of Cdc25A gene expression using a siRNA approach resulted in significant inhibition of ET or AII-dependent Cdk2 activity and (3)H-thymidine incorporation. The Cdc25A siRNA-mediated inhibition of ET or AII-induced Cdk2 activity and DNA synthesis was not additive with that produced by 1,25(OH)(2)D treatment. These data demonstrate that 1,25(OH)(2)D inhibits VSMC proliferation through a Cdc25A-dependent mechanism and suggest that this hormone may prove useful in the management of disorders characterized by aberrant proliferation of VSMC in the vascular wall.
Chen
Songcang
S
Diabetes Center, University of California at San Francisco, CA 94143-0540, United States. schen@diabetes.ucsf.edu
Law
Christopher S
CS
Grigsby
Christopher L
CL
Olsen
Keith
K
Gardner
David G
DG
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D002117:Calcitriol / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects*; D002478:Cells, Cultured; D002762:Cholecalciferol / Q000031:analogs & derivatives / Q000494:pharmacology; D051357:Cyclin-Dependent Kinase 2 / Q000378:metabolism; D016232:Endothelins / Q000494:pharmacology; D009131:Muscle, Smooth, Vascular / Q000166:cytology*; D051381:Rats; D020687:cdc25 Phosphatases / Q000502:physiology*
D016232:Endothelins; C113532:Ro 25-6760; D000804:Angiotensin II; D002762:Cholecalciferol; C495892:Cdk2 protein, rat; D051357:Cyclin-Dependent Kinase 2; D020687:cdc25 Phosphatases; D002117:Calcitriol
Proc Natl Acad Sci U S A. 1979 Jan;76(1):353-7
284351
J Biol Chem. 2004 Apr 2;279(14):13755-63
14742443
Cell. 1995 May 5;81(3):323-30
7736585
J Biol Chem. 2003 Dec 26;278(52):52052-60
14551212
Mol Cell Biol. 1999 Sep;19(9):6183-94
10454565
J Cardiovasc Pharmacol. 2007 Nov;50(5):519-25
18030061
Hypertension. 1989 Jun;13(6 Pt 2):954-9
2786849
Nat Med. 2002 Nov;8(11):1249-56
12411952
Atherosclerosis. 2006 May;186(1):20-8
16095599
J Clin Invest. 1994 Apr;93(4):1458-64
8163650
Curr Med Chem. 2007;14(17):1893-910
17627525
EMBO J. 1994 Sep 15;13(18):4302-10
7523110
J Biol Chem. 1999 Apr 16;274(16):11260-6
10196214
Circ Res. 2006 Oct 13;99(8):801-15
17038650
J Biol Chem. 1997 Nov 14;272(46):29207-11
9360999
Mol Cell Biol. 1999 Jul;19(7):4695-702
10373518
J Clin Invest. 1998 Aug 15;102(4):653-62
9710432
Genes Dev. 2000 Sep 15;14(18):2283-97
10995386
Science. 2000 May 26;288(5470):1425-9
10827953
J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):135-41
19961935
EMBO J. 1992 Nov;11(11):3995-4005
1396589
Ann Thorac Surg. 2007 Jul;84(1):317-23
17588453
J Clin Invest. 1991 Jun;87(6):1889-95
1645744
Annu Rev Cell Dev Biol. 1997;13:261-91
9442875
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2535-40
9482921
J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):156-62
17113979